Skip to main content
Terug
Watch Compare

Xilio Therapeutics, Inc.

Datakwaliteit: 100%
XLO
Nasdaq Manufacturing Chemicals
€ 8,55
▼ € 0,14 (-1,61%)
Marktkapitalisatie: 49,44 M
Prijs
€ 8,55
Marktkapitalisatie
49,44 M
Dagbereik
€ 8,55 — € 8,68
52-Weeksbereik
€ 6,47 — € 16,52
Volume
7.721
Openen € 8,68
50D / 200D Gem.
€ 7,91
8,06% above
50D / 200D Gem.
€ 9,57
10,65% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -5,51 M
Capital efficient — spends only 1,18% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)589,88%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-42,02%
Net Margin-80,05%
Op. Margin-95,92%

Veiligheid

Debt / Equity
N/A
Current Ratio2,20
Interest CoverageN/A

Waardering

PE (TTM)
-1,41
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,4 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -80,1 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 589,88% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 43,77 M Net Income (TTM) -35,04 M
ROE N/A ROA -26,19%
Gross Margin N/A Operating Margin -95,92%
Net Margin -80,05% Free Cash Flow (TTM) -5,51 M
ROIC -42,02% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,20
Interest Coverage N/A Asset Turnover 0,33
Working Capital 67,69 M Tangible Book Value -8,10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,41 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1,13
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -11,14%
Market Cap 49,44 M Enterprise Value -54,32 M
Per Share
EPS (Diluted TTM) -4,19 Revenue / Share 7,57
FCF / Share -0,95 OCF / Share -0,86
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,18% FCF Conversion 15,73%
SBC-Adj. FCF -11,09 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 43,77 M 6,34 M — — —
Net Income -35,04 M -58,24 M -76,40 M -88,22 M -75,80 M
EPS (Diluted) -4,19 -1,09 -2,78 -3,22 -13,52
Gross Profit — — — — —
Operating Income -41,98 M -60,58 M -79,13 M -89,15 M -75,04 M
EBITDA — — — — —
R&D Expenses 56,04 M 41,21 M 52,14 M 59,20 M 51,19 M
SG&A Expenses — — — — —
D&A 1,54 M 1,64 M 1,90 M 1,85 M 1,50 M
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 154,69 M 71,08 M 60,93 M 139,17 M 218,06 M
Total Liabilities 119,41 M 53,48 M 24,10 M 33,52 M 32,63 M
Shareholders' Equity 35,27 M 17,60 M 36,83 M 105,65 M 185,43 M
Total Debt — — — — —
Cash & Equivalents 137,53 M 55,29 M 44,70 M 120,39 M 198,05 M
Current Assets 145,03 M 60,23 M 48,13 M 124,50 M 202,52 M
Current Liabilities 56,27 M 27,26 M 15,96 M 21,12 M 12,78 M